Mission Statement

image - Mission Statement

53% of target number recruited

Active participation rate 93%, sample return rate 97%, Survey return rate 98%

526 patients recruited to the study

  • 200 CD
  • 146 UC
  • 224 Healthy participants


The microbiome and links to IBD

Inflammatory bowel disease (IBD), comprising the 2 main forms – Crohn’s disease and ulcerative colitis, is a global disease challenge. It affects approximately 1 in 250 Australians, with over 80,000 Australians currently living with IBD. IBD arises from a dysregulated immune response to alterations in the gut microbiota in susceptible individuals. Sufferers can endure numerous attacks or ‘flares’ followed by periods of relative remission; however, the disease trigger remains elusive. 

Being able to identify people at risk of IBD prior to symptoms, preventing symptom progression, and being able to define how patients are likely to respond to treatment, plays to the heart of IBD healthcare, namely, to improve patient health.

Who are The Sydney+ IBD Research consortium

The Sydney+ IBD Research consortium was initiated in 2018 to bring together clinicians and researchers to improve IBD patient care. The consortium is an active collaboration comprising early, mid and advanced-career clinicians/scientists with complementary strengths. The first aim of the network was to develop the infrastructure to ensure a unified approach to patient recruitment/sample collection – an issue which hampers many multi-centre studies. 

What is The Australian IBD Microbiome (AIM) Study

The Australian IBD Microbiome (AIM) Study is the inaugural study of the consortia and commenced recruitment in June 2019. The AIM study is a longitudinal cohort study with clinical data, patient-reported outcomes data, and biological samples collected from participants over a 24-month period.

The project will deliver:

  1. Microbial changes associated with onset of IBD symptoms
  2. Identification of Australian IBD microbial signatures to allow targeted intervention
  3. Generation of novel predictive models of direct translational utility to the clinic.
Study commencement date June 2019
Scheduled end date February 2025
Study Lead Professor Georgina Hold
Lead recruiting site St George Hospital, Kogarah, NSW 2017
Current recruiting area New South Wales
Recruiting sites St Vincent’s Hospital
Royal Prince Alfred Hospital
Liverpool Hospital
Concord Hospital
Sydney Children’s Hospital, Randwick
Sydney Children’s Hospital, Westmead
Wollongong Hospital
Blacktown Hospital
Sutherland Hospital
Canberra Hospital
AIM Study Funding

The AIM study receives or has received funds and or support from the following organisations:

Gastroenterological Society of Australia (GESA)

image - Mission Statement

Crohn’s Colitis Australia (CCA)

image - Mission Statement

St George and Sutherland Medical Research Foundation (SSMRF)

image - Mission Statement

Bioanalytical Mass Spectrometry Facility.
Mark Wainwright Analytical Centre, UNSW

image - Mission Statement